Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPTH(1-31)NH2 tablets versus placebo and open-label Forteo in postmenopausal osteoporosis
2010-020342-98Phase 2Completed
- Sponsor
- Unigene Laboratories, Inc.
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postmenopausal osteoporosis comparing rhPTH(1-31)NH2 tablets, matching placebo tablets and open-label Forteo (3 arms). Primary endpoints: Percent change from baseline in lumbar spine bone mineral density, Safety and tolerability and 6 more. Started Jan 2011; status: completed.
02
Drugs
PTH(1-31)teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2010-020342-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020342-98.